Justin R. Arnall, PharmD, BCOP, FCCP

Fitusiran in Hemophilia: A Novel Therapeutic Approach Targeting Antithrombin

Fitusiran was FDA approved on March 28, 2025, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies). This article contains an over...